Scarica l'app Stockscreener
2.67
0.74%
-0.02
Dopo l'orario di chiusura:
2.51
-0.16
-5.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BLRX Giù?
Forum
Previsione
Frazionamento azionario
Bioline Rx Ltd Adr Borsa (BLRX) Ultime notizie
BioLineRx Earnings Call Highlights GLIX1 Momentum - TipRanks
BioLineRx (NASDAQ: BLRX) Announces $3.3M Net Raise via 480,696 ADSs at $2.78 Each - Kalkine Media
BioLineRx Raises $3.75 Million in August Registered Direct Offering and Warrant Deal - TipRanks
Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances - Investing.com
BioLineRx Advances GLIX1 Oncology Program and Posts Q2 2026 Results - TipRanks
BioLineRx stock falls on $3.75M share offering plan - Investing.com India
BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility - TipRanks
BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement - Barchart.com
BioLineRx raises $3.75 million in registered direct offering - Investing.com
What Could BioLineRx (NASDAQ:BLRX) Reveal as NASDAQ Eyes Results? - Kalkine Media
Why Are Nasdaq, S&P 500 Futures Falling Premarket? NVDA, SKHY, SPCX, TSLA, MRNA, MSTR, PURR, WMT Stocks In Focus - TradingView
BioLineRx Sets September 23, 2026 Shareholders Meeting to Boost Capital and Approve New Equity Awards - TipRanks
Serina Therapeutics: Buy Rating Reiterated, $11 Price Target Maintained on Strong SER-252 Clinical Progress - TipRanks
Analyst Justin Walsh Reiterates Buy on NeuroOne, Maintains $8 Target on Partner-Driven RF Ablation Growth and Pipeline Upside - TipRanks
Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS) - The Globe and Mail
Analysts Offer Insights on NA Companies: Starz Entertainment Corp (STRZ), Bluelinx Holdings (BXC) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Price to sales forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026 - Investing.com
Price to earnings forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
Enterprise value to revenue forward of BioLineRX Ltd. Sponsored ADR – MUN:YP2 - TradingView
BioLineRx reports preclinical data on GLIX1 with PARP inhibitor - Investing.com
BioLineRx and Hemispherian Report GLIX1–PARP Synergy in Ovarian Cancer Model, Plan Trial Expansion - TipRanks
India Celiac Disease Treatment Market Size & Outlook, 2033 - Grand View Research
YP2 Forecast — Price Target — Prediction for 2027 - TradingView
A41038 Forecast — Price Target — Prediction for 2027 - TradingView
BLRX Forecast — Price Target — Prediction for 2027 - TradingView
Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), TScan Therapeutics (TCRX) and PACS Group Inc (PACS) - The Globe and Mail
Glioblastoma Clinical Trial Landscape Expands: Over 200 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
BioLineRx Earnings Call: Pipeline Momentum, Profit Squeeze - The Globe and Mail
JonesTrading Reaffirms Their Buy Rating on Bioline RX Ltd Sponsored ADR (BLRX) - The Globe and Mail
BioLineRx shares rise 4% on first patient dosed in cancer trial - Investing.com
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results By Investing.com - Investing.com South Africa
Earnings call transcript: BioLineRx’s Q1 2026 reveals mixed results - Investing.com
BioLineRx shares rise 4% on first patient dosed in cancer trial By Investing.com - Investing.com South Africa
BioLineRx Kicks Off GLIX1 Clinical Trial as Q1 2026 Loss Widens on Higher R&D Spend - TipRanks
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
BLRXBioline Rx Ltd ADR Stock Price and Quote - Finviz
BioLineRx and Hemispherian Showcase New GLIX1 Data Ahead of ASCO 2026 as First-in-Human GBM Trial Enrolls - TipRanks
BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - Barchart.com
BLRX Technical Analysis | Trend, Signals & Chart Patterns | BIOLINERX LTD-SPONS ADR (NASDAQ:BLRX) - ChartMill
BioLineRx to Report First Quarter 2026 Results on May 27, 2026 - Morningstar
BioLineRx and Hemispherian Report Strong Preclinical GLIX1 Data in Temozolomide-Resistant Glioblastoma - TipRanks
BioLineRx reports preclinical data for GBM treatment GLIX1 - Investing.com
BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts - Barchart.com
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Immunic (IMUX) and Protara Therapeutics (TARA) - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Number of shareholders of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Definium Therapeutics (DFTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: RenovoRx (RNXT) and Protara Therapeutics (TARA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI) - The Globe and Mail
Head & Shoulders InverseStock ScreenerCharts - Finviz
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial - TipRanks
BioLineRx doses first patient in glioblastoma drug trial By Investing.com - Investing.com South Africa
BioLineRx doses first patient in glioblastoma drug trial - Investing.com
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM) - Barchart.com
Analysts’ Top Healthcare Picks: Perspective Therapeutics (CATX), Nektar Therapeutics (NKTR) - The Globe and Mail
Analysts’ Top Healthcare Picks: Rapport Therapeutics, Inc. (RAPP), Abbott Laboratories (ABT) - The Globe and Mail
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target - TipRanks
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (JSPR), Alto Neuroscience, Inc. (ANRO) and Viridian Therapeutics (VRDN) - The Globe and Mail
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):